Neoadjuvant T-DXd produced faster imaging responses vs ddAC in DESTINY-Breast11, but imaging poorly predicted pCR.
|Videos|October 3, 2012
Photos From the European Society for Medical Oncology Congress
Author(s)Onclive Team
Photos from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna from September 28 to October 2, in Vienna, Austria.
Advertisement
Photos from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna from September 28 to October 2, in Vienna, Austria.
The top three articles from OncLive's coverage included:
- Updated Data Show T-DM1 Improves Overall Survival in HER2-Positive Breast Cancer
- BRAF Inhibitor Plus MEK Inhibitor Encouraging in Metastatic Melanoma
- Updated Regorafenib Survival Results Confirm Effectiveness
<<<
Advertisement
Related to this article
Abemaciclib plus fulvestrant showed a numerical yet nonsignificant overall survival trend after CDK4/6 inhibitor progression in final postMONARCH data.
INCB123667 with bevacizumab showed antitumor activity in heavily pretreated, cyclin E1–overexpressing platinum-resistant ovarian cancer.
Selective CDK4 inhibitor atirmociclib plus fulvestrant reduced risk of progression or death by 40% vs investigator's choice of therapy in the phase 2 FOURLIGHT-1 trial.
Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.
The claudin 6–targeted antibody-drug conjugate ixotatug vedotin showed antitumor activity in recurrent germ cell tumors, including after transplant.
An exploratory analysis of the phase 3 KEYNOTE-B15 trial found that ctDNA status was strongly prognostic for event-free survival regardless of treatment arm.
The KEYNOTE-866 trial did not meet its EFS primary end point with perioperative pembrolizumab added to neoadjuvant cisplatin and gemcitabine.
Advertisement
Advertisement
Trending on OncLive
1
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
2
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
3
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
4
Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC
5